Author

Natalie Dimier

Observed names: Dimier, Natalie, N. Dimier, N.J. Dimier

Observed institutions: Roche (Switzerland), Roche (United Kingdom), University of Reading

ORCID: 0000-0002-8537-4962

Observed ORCID: 0000-0002-8537-4962

OpenAlex ID: A5029160106

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

2021 · Martin Hutchings, Franck Morschhauser, et al. · Journal of Clinical Oncology · 437

PDF

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

2017 · for the ERIVANCE BCC Investigators, Aleksandar Sekulic, et al. · BMC Cancer · 418

PDF

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

2016 · Laurie H Sehn, Neil Chua, et al. · The Lancet Oncology · 350

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

2017 · N. Basset-Séguin, A. Hauschild, et al. · European Journal of Cancer · 287

PDF

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

2021 · Ann-Marie E. Bröske, Koorosh Korfi, et al. · Blood Advances · 84

PDF

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

2017 · Natalie Dimier, Paul Delmar, et al. · Blood · 83

PDF

Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

2025 · Qian Shi, Bruno Paiva, et al. · Journal of Clinical Oncology · 44

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

2018 · Martin Hutchings, Gloria Iacoboni, et al. · Blood · 31

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

2018 · Stephen Couban, Giulia Benevolo, et al. · Journal of Hematology & Oncology · 30

PDF

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

2019 · Franck Morschhauser, Carmelo Carlo-Stella, et al. · Blood · 27

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study

2018 · Johan Hansson, Karen Bartley, et al. · European Journal of Dermatology · 26

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

2019 · Martin Hutchings, Giuseppe Gritti, et al. · Blood · 25

CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

2022 · Martin Hutchings, Carmelo Carlo-Stella, et al. · Blood · 23

Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072

2024 · Martin Hutchings, Michael J. Dickinson, et al. · Blood · 22

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

2018 · Dale Bixby, Richard Noppeney, et al. · British Journal of Haematology · 22

PDF

2016 · Bruce D. Cheson, Peter C. Trask, et al. · Annals of Hematology · 22

PDF

OA-05 Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses

2023 · Simon Harrison, Caroline Hasselbalch Riley, et al. · Clinical Lymphoma Myeloma & Leukemia · 21

Cd20‐tcb (rg6026), a Novel “2:1” Format T‐cell‐engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/refractory B‐cell Non‐hodgkin's Lymphoma

2019 · M.J. Dickinson, F. Morschhauser, et al. · Hematological Oncology · 15

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

2019 · for the ERIVANCE BCC Investigators, Aleksandar Sekulic, et al. · BMC Cancer · 15

PDF

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

2019 · Chi-Chung Li, Brendan Bender, et al. · Blood · 14

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium

2025 · Michael Boyiadzis, Andrew H. Wei, et al. · Cancer · 11

Population Pharmacokinetics and Novel Exposure-Response Analyses to Inform Optimal Biologic Dose Selection for CD20-TCB, a T-Cell-Engaging Bispecific Antibody, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

2019 · Nassim Djebli, Felix Jaminion, et al. · Blood · 8

An investigation into the two‐stage meta‐analytic copula modelling approach for evaluating time‐to‐event surrogate endpoints which comprise of one or more events of interest

2017 · Natalie Dimier, Susan Todd · Pharmaceutical Statistics · 8

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

2023 · Koorosh Korfi, Ailsa Christiansen, et al. · Blood · 7

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

2019 · Ann-Marie E Bröske, Ian James, et al. · Blood · 7

Works count: 47

Citation count: 2,081

H-index: 17

I10-index: 21